Forget what the trial proved about aficamten. Ask instead what it does to Cytokinetics as a business. That reframe is where the investment thesis lives this week.
On August 28, 2026, Cytokinetics announced that ACACIA-HCM met both dual primary endpoints, demonstrating statistically significant improvements from baseline to Week 36 versus placebo in both the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score and maximal exercise performance (peak VO2). The data were presented in a Hot Line session at the European Society of Cardiology Congress in Munich and simultaneously published in the New England Journal of Medicine. Cytokinetics said ACACIA-HCM is the first Phase 3 clinical trial to successfully demonstrate statistically significant improvements across both patient-reported and physician-assessed endpoints in non-obstructive HCM.
What the Numbers Actually Say
The trial showed improvements at Week 36 in KCCQ-CSS (least-squares mean difference +3.0 points, P=0.021) and peak VO2 (+0.67 mL/kg/min, P=0.003) for aficamten versus placebo. Both endpoints are meaningful to regulators and physicians: one captures how patients feel, the other captures what their hearts can physically do. The treatment effect was consistent across prespecified subgroups, including baseline ejection fraction, atrial fibrillation status, genotype, age, sex, and whether patients were receiving background beta-blocker therapy. That kind of consistency across subgroups is exactly what an FDA reviewer wants to see before signing off on a supplemental indication.
No new safety signals were identified, although LVEF below 50% occurred in about 10% of aficamten patients versus about 1% on placebo, with two aficamten patients experiencing serious heart-failure events; most ejection-fraction declines were reported as reversible with treatment interruption. The reversibility matters. It suggests the signal is manageable rather than structural, which keeps the benefit-risk calculus favorable.
The Commercial Arithmetic
The real story is what a non-obstructive label does to the revenue model. HCM affects an estimated 1 in 500 individuals worldwide, and non-obstructive HCM accounts for approximately 30% to 70% of cases. Compared with obstructive HCM, treatment options in non-obstructive HCM are limited, with current strategies providing only symptomatic relief. Aficamten would enter a segment where no targeted therapy exists.
Myqorzo generated net product revenue of about $25 million in the second quarter of 2026, a launch still in its early months. The company held approximately $1.7 billion in cash, cash equivalents, and investments as of June 30, 2026. That balance sheet removes one of the perennial risks for a single-product specialty biopharma: the need to raise capital at an inopportune moment. Cytokinetics can fund a full nHCM commercial buildout and still have runway left for its pipeline.
Following the positive ACACIA-HCM results, the company said it plans to submit a supplemental New Drug Application in Q4 2026. A standard FDA review clock puts a potential approval decision around late 2027.
The ESC Context: One Win, One Miss
Munich produced a striking contrast. While Cytokinetics was presenting ACACIA-HCM, the same Hot Line session slate delivered unwelcome news from a very different cardiology program. The Phase 3 CARDIO-TTRansform trial investigating eplontersen in transthyretin amyloid cardiomyopathy did not meet its primary efficacy endpoint: among 1,432 patients with wild-type or hereditary ATTR-CM, the composite of cardiovascular mortality and recurrent cardiovascular clinical events did not differ significantly between eplontersen and placebo through 140 weeks. In this contemporary patient population treated with standard of care, including many patients on a stabilizer, adding eplontersen did not provide a statistically significant benefit. For Ionis and AstraZeneca, the miss raises questions about eplontersen’s path forward in cardiac indications.
Bull Case, Bear Case
The bull case is direct. Aficamten already works in obstructive HCM, Myqorzo is launching in multiple geographies, and ACACIA-HCM just validated a second indication with no approved competition. The company has said its increased R&D and SG&A guidance is primarily driven by commercial readiness investments to support the potential 2027 launch of Myqorzo in nHCM. Management is already spending as if the label is coming.
The bear case centers on execution. Converting ACACIA-HCM’s clean data into a second commercial launch requires physician education in a patient population that has historically been difficult to identify and treat. The ejection fraction safety signal, while manageable, will require careful prescriber messaging. And Bristol Myers Squibb’s Camzyos holds a head start in cardiologist mindshare that Cytokinetics will need to overcome market by market.
What Investors Should Watch Next
The sNDA filing date, Q3 Myqorzo revenue, and any FDA feedback on the MAPLE-HCM supplemental application (PDUFA date: November 14, 2026) are the three events that will define the next 90 days. If Myqorzo’s quarterly revenue continues its ramp and the sNDA lands on schedule, the investment thesis that aficamten can address the full HCM spectrum becomes very difficult to argue against.
